PREPARATION AND IN-VITRO EVALUATION OF MAGNETIC MICROSPHERE-METHOTREXATE CONJUGATE DRUG-DELIVERY SYSTEMS

被引:25
作者
DEVINENI, D
BLANTON, CD
GALLO, JM
机构
[1] FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111
[2] UNIV GEORGIA,COLL PHARM,ATHENS,GA 30602
关键词
D O I
10.1021/bc00032a008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Magnetic microsphere-methoxtrexate (MM-MTX) conjugates prepared by several different methods were analyzed for their suitability for in vivo use. MM-MTX were prepared by the following methods: (A) reaction of MTX with poly(ethylene glycol) 1500 (PEG) to form a poly(ethylene glycol)methotrexate conjugate (PEGMTX) which was then added to a ferrous/ferric ion salt solution to give MM-MTX I; (B) reaction of ferrous/ferric ion salts with PEG to give a ferromagnetic polymer complex which was then coupled with MTX to give MM-MTX II; (C) MM-MTX IIIA were prepared by reacting MTX with amino-terminated magnetic microspheres, commercially available, in the presence of 1-ethyl-3,3 -bis(methylamino)propylcarbodiimide (EDCI); (D) reaction of aminohexanol with di-tert-butyl dicarbonate to form an [N-(tert-butoxycarbonyl)amino]hexanol (t-Boc-AH), which was then coupled with MTX in the presence of 1,3-dicyclohexylcarbodiimide and 4-pyrrolidinopyridine to give a t-Boc-AH-MTX conjugate, which was then saturated with hydrogen chloride to give an aminohexanol-methotrexate (AH-MTX) conjugate. MM-MTX IIIB were then prepared by reacting AH-MTX with carboxyl-terminated magnetic microspheres, commercially available, in the presence of EDCI and 4-(dimethylamino)pyridine. The identity of MTX conjugates was confirmed using ultraviolet, infrared, and nuclear magnetic resonance spectroscopy. Drug content of the magnetic microsphere-methotrexate conjugates as determined by HPLC was 0.45% (w/w), 4.0% (w/w), and 6.3% (w/w) MTX for MM-MTX I, MM-MTX II, and MM-MTX IIIB, respectively. In vitro stability studies of MM-MTX in rat plasma revealed that approximately 97% (w/w) (MM-MTX I), 74% (w/w) (MM-MTX II), and 11% (w/w) (MM-MTX IIIB) of MTX was released from MM-MTX over a 24 h period. The ability to increase drug loading, compared to matrix microsphere systems, via an ester linkage offers another dimension to tumor delivery of chemotherapeutic agents.
引用
收藏
页码:203 / 210
页数:8
相关论文
共 48 条
[1]   PRERADIATION HIGH-DOSE INTRAVENOUS METHOTREXATE WITH LEUCOVORIN RESCUE FOR UNTREATED PRIMARY CHILDHOOD BRAIN-TUMORS [J].
ALLEN, JC ;
WALKER, R ;
ROSEN, G .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :649-653
[2]  
ALLEN JC, 1981, ANN NEUROL, V10, P293
[3]  
BERTINO JR, 1963, CANCER RES, V23, P1286
[4]  
CHU BCF, 1977, MOL PHARMACOL, V13, P80
[5]  
DEVINENI D, 1994, IN PRESS J NEUROONCO
[6]  
DJERASSI I, 1988, P AN M AM SOC CLIN, V7, P82
[7]   MAGNETISM IN MEDICINE [J].
FREEMAN, MW ;
ARROTT, A ;
WATSON, JHL .
JOURNAL OF APPLIED PHYSICS, 1960, 31 (05) :S404-S405
[8]  
FUNG WP, 1979, J NATL CANCER I, V62, P1261
[9]   EVALUATION OF DRUG DELIVERY FOLLOWING THE ADMINISTRATION OF MAGNETIC ALBUMIN MICROSPHERES CONTAINING ADRIAMYCIN TO THE RAT [J].
GALLO, JM ;
GUPTA, PK ;
HUNG, CT ;
PERRIER, DG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (03) :190-194
[10]  
Ghosh M K, 1989, Drug Des Deliv, V4, P13